SCHEMBL13850849

SCHEMBL13850849

COC(=O)c1cc(C(=O)C(=O)O)c2cc(Cc3ccc(F)cc3)cnc2c1OCc1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.42
LMNA P02545 3/20 0.41
HPGD P15428 1/20 0.41
FFAR4 Q5NUL3 1/20 0.40
PLA2G2A P14555 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.38
KDM5A P29375 1/20 0.38
KDM5B Q9UGL1 1/20 0.38
NR1H2 P55055 1/20 0.37
USP2 O75604 1/20 0.37
ALDH1A1 P00352 1/20 0.37
TSHR P16473 1/20 0.37
HSD17B10 Q99714 1/20 0.37
TP53 P04637 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
RAB9A P51151 1/20 0.36
KMT2A Q03164 1/20 0.36
CCNB2 O95067 1/20 0.36
CCNE2 O96020 1/20 0.36
CDK1 P06493 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13850852 0.94 MAPT (0.41) MAPTLMNAHPGDFFAR4PLA2G2A
SCHEMBL13850761 0.93 MAPT (0.43) MAPTLMNAHPGDFFAR4PLA2G2A
SCHEMBL13850850 0.92 MAPT (0.42) MAPTLMNAHPGDFFAR4PLA2G2A
SCHEMBL13850816 0.91 MAPT (0.42) MAPTLMNAHPGDFFAR4PLA2G2A
SCHEMBL13850815 0.89 MAPT (0.43) MAPTLMNAHPGDFFAR4PLA2G2A
SCHEMBL13850787 0.89 MAPT (0.42) MAPTLMNAHPGDFFAR4PLA2G2A
SCHEMBL13850786 0.89 MAPT (0.44) MAPTLMNAHPGDFFAR4PLA2G2A
SCHEMBL14193475 0.88 MAPT (0.40) MAPTLMNAHPGDFFAR4PLA2G2A
SCHEMBL13850788 0.88 MAPT (0.41) MAPTLMNAHPGDFFAR4PLA2G2A
SCHEMBL3872057 0.88 MAPT (0.42) MAPTLMNAHPGDFFAR4PLA2G2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090118233-A1 Heterocyclic compounds having inhibitory activity against HIV integrase MURAI HITOSHI 2009-05-07 US disclosed
US-7358249-B2 Heterocyclic compounds having inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2008-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118233-A1 Heterocyclic compounds having inhibitory activity against HIV integrase CYP3A7, CDK7, CYP2A7 MAPT 4308/4885LMNA 1842/4885HPGD 3035/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.